Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on July 24, 2013. The report discloses a material event regarding the departure of a senior officer and the execution of a Transition and Separation Agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and severance terms.
Material Changes and Executive Departure
On July 24, 2013, Codexis, Inc. entered into a Transition and Separation Agreement with David L. Anton, the former Senior Vice President of BioIndustrials. Key terms include:
- Transition Period: Dr. Anton served as Advisor to the CEO from June 1, 2013, to August 31, 2013.
- Transition Compensation: Continued base salary of $27,895.84 per month and continued vesting of existing stock options.
- Severance Package: Upon completion of the transition and execution of a release of claims, Dr. Anton is entitled to:
- Six bi-monthly severance payments of $13,948 each.
- A lump-sum pro rata bonus for fiscal year 2013 totaling $61,800.
- Payment of COBRA premiums for medical, dental, and vision coverage until November 30, 2013, or until comparable coverage is obtained elsewhere.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary contingency noted is the requirement for Dr. Anton to provide a full general release of claims and comply with confidentiality and invention agreements to receive the post-transition severance benefits.
Key Facts for Investor Verification
- Confirmation of the total cash severance obligation ($61,800 bonus + $83,688 in bi-monthly payments).
- Verification of the impact of this executive departure on the BioIndustrials division.
- Review of the full Transition and Separation Agreement filed as an exhibit to the subsequent Form 10-Q for the quarter ended June 30, 2013.